Published in Neurogastroenterol Motil on November 21, 2011
Visceral hypersensitivity and electromechanical dysfunction as therapeutic targets in pediatric functional dyspepsia. World J Gastrointest Pharmacol Ther (2014) 0.86
Effect of nutritional rehabilitation on gastric motility and somatization in adolescents with anorexia. J Pediatr (2013) 0.81
Gastric emptying scintigraphy results in children are affected by age, anthropometric factors, and study duration. Neurogastroenterol Motil (2015) 0.77
Obesity and functional gastrointestinal diseases in children. J Neurogastroenterol Motil (2014) 0.75
Abdominal migraine in children: association between gastric motility parameters and clinical characteristics. BMC Gastroenterol (2016) 0.75
Serum levels of ghrelin and obestatin in children with symptoms suggestive of delayed gastric emptying of unclear etiology. Ann Gastroenterol (2015) 0.75
The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther (2003) 3.41
Improvement of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary studies. N Engl J Med (1990) 2.67
Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome. Aliment Pharmacol Ther (2011) 2.42
Acid, nonacid, and gas reflux in patients with gastroesophageal reflux disease during ambulatory 24-hour pH-impedance recordings. Gastroenterology (2001) 2.41
Development and validation of a patient-assessed gastroparesis symptom severity measure: the Gastroparesis Cardinal Symptom Index. Aliment Pharmacol Ther (2003) 2.28
Weakly acidic reflux in patients with chronic unexplained cough during 24 hour pressure, pH, and impedance monitoring. Gut (2005) 2.20
Itopride in functional dyspepsia: results of two phase III multicentre, randomised, double-blind, placebo-controlled trials. Gut (2007) 2.11
Determinants of symptoms in functional dyspepsia: gastric sensorimotor function, psychosocial factors or somatisation? Gut (2008) 2.00
Clinical trial guidelines for pharmacological treatment of irritable bowel syndrome. Aliment Pharmacol Ther (2003) 1.82
Development and psychometric evaluation of the patient assessment of upper gastrointestinal symptom severity index (PAGI-SYM) in patients with upper gastrointestinal disorders. Qual Life Res (2004) 1.76
Relationship between symptoms and ingestion of a meal in functional dyspepsia. Gut (2008) 1.67
Relevance of ineffective oesophageal motility during oesophageal acid clearance. Gut (2003) 1.61
Cannabinoid receptor 1 signalling dampens activity and mitochondrial transport in networks of enteric neurones. Neurogastroenterol Motil (2009) 1.59
Randomised clinical trial: effects of monotherapy with ADX10059, a mGluR5 inhibitor, on symptoms and reflux events in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther (2011) 1.56
Ambulatory gastrojejunal manometry in severe motility-like dyspepsia: lack of correlation between dysmotility, symptoms, and gastric emptying. Gut (1998) 1.54
Associations between gastric sensorimotor function, depression, somatization, and symptom-based subgroups in functional gastroduodenal disorders: are all symptoms equal? Neurogastroenterol Motil (2012) 1.51
Assessment of gastric sensorimotor function in paediatric patients with unexplained dyspeptic symptoms and poor weight gain. Neurogastroenterol Motil (2007) 1.50
Review article: a comparison of glucagon-like peptides 1 and 2. Aliment Pharmacol Ther (2012) 1.48
Composition of the postprandial refluxate in patients with gastroesophageal reflux disease. Am J Gastroenterol (2001) 1.47
Second-generation antipsychotics and constipation: a review of the literature. Eur Psychiatry (2010) 1.46
Different regional brain activity during physiological gastric distension compared to balloon distension: a H2 15O-PET study. Neurogastroenterol Motil (2010) 1.45
Review article: acidity and volume of the refluxate in the genesis of gastro-oesophageal reflux disease symptoms. Aliment Pharmacol Ther (2007) 1.44
Multiple rapid swallowing: a complementary test during standard oesophageal manometry. Neurogastroenterol Motil (2009) 1.43
Pneumatic dilation for achalasia--the way forward. Aliment Pharmacol Ther (2011) 1.40
Extraoesophageal manifestations of gastro-oesophageal reflux. Gut (2005) 1.40
Erythromycin accelerates gastric emptying by inducing antral contractions and improved gastroduodenal coordination. Gastroenterology (1992) 1.33
Functional dyspepsia, delayed gastric emptying, and impaired quality of life. Gut (2005) 1.32
Impaired gastric accommodation and its role in dyspepsia. Gut (2006) 1.31
Psychometric performance and clinical meaningfulness of the Patient Assessment of Constipation-Quality of Life questionnaire in prucalopride (RESOLOR) trials for chronic constipation. Neurogastroenterol Motil (2009) 1.27
Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut (2003) 1.26
Clinical trial: a randomized-controlled crossover study of intrapyloric injection of botulinum toxin in gastroparesis. Aliment Pharmacol Ther (2007) 1.24
Involvement of two different pathways in the motor effects of erythromycin on the gastric antrum in humans. Gut (1998) 1.24
The role of acid and duodenal gastroesophageal reflux in symptomatic GERD. Am J Gastroenterol (2001) 1.23
Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints. Aliment Pharmacol Ther (2012) 1.22
Improved diagnosis of gastro-oesophageal reflux in patients with unexplained chronic cough. Aliment Pharmacol Ther (2007) 1.21
Predictors of the placebo response in functional dyspepsia. Aliment Pharmacol Ther (2006) 1.20
Diagnosis and management of non-erosive reflux disease--the Vevey NERD Consensus Group. Digestion (2009) 1.19
Immune dysfunction in patients with functional gastrointestinal disorders. Neurogastroenterol Motil (2008) 1.18
Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia - 100 mg t.i.d. is an optimal dosage. Neurogastroenterol Motil (2010) 1.13
Review article: the role of gastric motility in the control of food intake. Aliment Pharmacol Ther (2011) 1.13
Perception of changes in wall tension of the proximal stomach in humans. Gut (2001) 1.12
Role of nitric oxide in fasting gastric fundus tone and in 5-HT1 receptor-mediated relaxation of gastric fundus. Am J Physiol (1999) 1.11
P2Y1 receptors mediate inhibitory neuromuscular transmission and enteric neuronal activation in small intestine. Neurogastroenterol Motil (2007) 1.11
Intestinal immune activation in presumed post-infectious functional dyspepsia. Neurogastroenterol Motil (2009) 1.11
Determinants of symptom pattern in idiopathic severely delayed gastric emptying: gastric emptying rate or proximal stomach dysfunction? Gut (2006) 1.10
Sumatriptan, a selective 5-HT1 receptor agonist, induces a lag phase for gastric emptying of liquids in humans. Am J Physiol (1997) 1.10
Reproducibility of gastric barostat studies in healthy controls and in dyspeptic patients. Am J Gastroenterol (2001) 1.09
Functional dyspepsia symptoms, gastric emptying and satiety provocative test: analysis of relationships. Scand J Gastroenterol (2001) 1.09
Dyspeptic symptoms in the general population: a factor and cluster analysis of symptom groupings. Neurogastroenterol Motil (2009) 1.07
Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying: randomized controlled study evaluation by real-time ultrasonography. Neurogastroenterol Motil (2012) 1.05
Automated impedance manometry analysis as a method to assess esophageal function. Neurogastroenterol Motil (2014) 1.04
ATP-dependent paracrine communication between enteric neurons and glia in a primary cell culture derived from embryonic mice. Neurogastroenterol Motil (2009) 1.04
Pharmacological management of constipation. Neurogastroenterol Motil (2009) 1.04
Effects of capsaicin on the sensorimotor function of the proximal stomach in humans. Aliment Pharmacol Ther (2004) 1.01
On the existence and location of cardiac mucosa: an autopsy study in embryos, fetuses, and infants. Gut (2003) 1.00
Altered intestinal microbiota in irritable bowel syndrome. Neurogastroenterol Motil (2010) 1.00
Review article: endpoints used in functional dyspepsia drug therapy trials. Aliment Pharmacol Ther (2011) 1.00
Duodenogastroesophageal reflux and esophageal mucosal injury in mechanically ventilated patients. Gastroenterology (1999) 0.99
Acotiamide hydrochloride (Z-338), a novel prokinetic agent, restores delayed gastric emptying and feeding inhibition induced by restraint stress in rats. Neurogastroenterol Motil (2008) 0.99
Relevance of mild ineffective oesophageal motility (IOM) and potential pharmacological reversibility of severe IOM in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther (2007) 0.99
Randomised clinical trial: the long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation. Aliment Pharmacol Ther (2014) 0.99
Levels of satisfaction with current chronic constipation treatment options in Europe - an internet survey. Aliment Pharmacol Ther (2012) 0.99
Mechanisms underlying duodeno-gastric reflux in man. Neurogastroenterol Motil (2005) 0.98
Influence of erythromycin on gastric emptying and meal related symptoms in functional dyspepsia with delayed gastric emptying. Gut (2005) 0.98
Influence of citalopram, a selective serotonin reuptake inhibitor, on oesophageal hypersensitivity: a double-blind, placebo-controlled study. Aliment Pharmacol Ther (2006) 0.98
Brain-derived neurotrophic factor amplifies neurotransmitter responses and promotes synaptic communication in the enteric nervous system. Gut (2007) 0.97
Characterization of myenteric neuropathy in the jejunum of spontaneously diabetic BB-rats. Neurogastroenterol Motil (2008) 0.97
Obesity and metabolic syndrome: an inflammatory condition. Dig Dis (2012) 0.97
Energy homeostasis and gastric emptying in ghrelin knockout mice. J Pharmacol Exp Ther (2005) 0.96
IL-1beta and IL-6 excite neurones and suppress cholinergic neurotransmission in the myenteric plexus of the guinea pig. Neurogastroenterol Motil (2000) 0.96
Influence of intrapyloric botulinum toxin injection on gastric emptying and meal-related symptoms in gastroparesis patients. Aliment Pharmacol Ther (2006) 0.95
An impedance-manometry based method for non-radiological detection of pharyngeal postswallow residue. Neurogastroenterol Motil (2012) 0.95
Biosynthesis of riboflavin. Lumazine synthase of Escherichia coli. J Biol Chem (1996) 0.95
Imaging of neuronal activity in the gut. Curr Opin Pharmacol (2001) 0.94
Factors associated with co-morbid irritable bowel syndrome and chronic fatigue-like symptoms in functional dyspepsia. Neurogastroenterol Motil (2011) 0.94
Relationship between symptom pattern, assessed by the PAGI-SYM questionnaire, and gastric sensorimotor dysfunction in functional dyspepsia. Neurogastroenterol Motil (2009) 0.94
New algorithm for the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther (2007) 0.94
Significance of arrhythmias during the first 24 hours of acute myocardial infarction treated with alteplase and effect of early administration of a beta-blocker or a bradycardiac agent on their incidence. Circulation (1994) 0.93
Intragastric distribution of a standardized meal in health and functional dyspepsia: correlation with specific symptoms. Neurogastroenterol Motil (2003) 0.92
Role of serotonin in gastrointestinal physiology and pathology. Minerva Endocrinol (2011) 0.92
A pilot study of the effects of the somatostatin analog pasireotide in postoperative dumping syndrome. Neurogastroenterol Motil (2014) 0.91
Randomized clinical trial: rikkunshito in the treatment of functional dyspepsia--a multicenter, double-blind, randomized, placebo-controlled study. Neurogastroenterol Motil (2014) 0.91
A survey on gastroenterology training in Europe. Gut (2002) 0.90
The irritable bowel syndrome. Saudi J Gastroenterol (1998) 0.90
A one-year follow-up study of endoluminal gastroplication (Endocinch) in GERD patients refractory to proton pump inhibitor therapy. Dig Dis Sci (2005) 0.90
Cortical deactivations during gastric fundus distension in health: visceral pain-specific response or attenuation of 'default mode' brain function? A H2 15O-PET study. Neurogastroenterol Motil (2008) 0.90
Risk factors for impaired health-related quality of life in functional dyspepsia. Aliment Pharmacol Ther (2010) 0.90
Chronic middle ear disease and gastroesophageal reflux disease: a causal relation? Otol Neurotol (2001) 0.90
Promotility medications--now and in the future. Dig Dis (2006) 0.89
Analysis of ambulatory duodenogastroesophageal reflux monitoring. Dig Dis Sci (2000) 0.89
The quest for biomarkers in IBS-where should it lead us? Neurogastroenterol Motil (2014) 0.89
GPR39, a receptor of the ghrelin receptor family, plays a role in the regulation of glucose homeostasis in a mouse model of early onset diet-induced obesity. J Neuroendocrinol (2011) 0.89
FDA and EMA end points: which outcome end points should we use in clinical trials in patients with irritable bowel syndrome? Neurogastroenterol Motil (2013) 0.89
Dyspeptic patients with visceral hypersensitivity: sensitisation of pain specific or multimodal pathways? Gut (2005) 0.89
Role of the AMP-activated protein kinase (AMPK) signaling pathway in the orexigenic effects of endogenous ghrelin. Regul Pept (2011) 0.88
Influence of intra-oesophageal capsaicin instillation on heartburn induction and oesophageal sensitivity in man. Neurogastroenterol Motil (2009) 0.88
Influence of radiofrequency energy delivery at the gastroesophageal junction (the Stretta procedure) on symptoms, acid exposure, and esophageal sensitivity to acid perfusion in gastroesophagal reflux disease. Dig Dis Sci (2007) 0.88